Chimeric antigen receptor based cellular therapy for treatment Of T-cell malignancies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013423" target="_blank" >RIV/00023736:_____/22:00013423 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/22:10444948 RIV/00216208:11110/22:10444948

Result on the web

<a href="https://doi.org/10.3389/fonc.2022.876758" target="_blank" >https://doi.org/10.3389/fonc.2022.876758</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fonc.2022.876758" target="_blank" >10.3389/fonc.2022.876758</a>

Result language

angličtina

Original language name

Chimeric antigen receptor based cellular therapy for treatment Of T-cell malignancies

Original language description

T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of 28 different entities. Most of these malignancies are aggressive with rather poor prognosis. Prognosis of relapsed/refractory (R/R) disease is especially dismal, with an expected survival only several months after progression.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in oncology

ISSN

2234-943X

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

[May]

Country of publishing house

CH - SWITZERLAND

Number of pages

15

Pages from-to

"art. no. 876758"

UT code for WoS article

000798481200001

EID of the result in the Scopus database

2-s2.0-85130693321